This combined evaluation of RB1CC1/RB1/p53 can provide a benefit for the clinical management of breast cancer patients, and improve upon the individual evaluations of RB1, p53 or triple-negativity [ER(−), PR(−) and HER2(−)] to predict the long-term prognosis of breast cancer patients[1], [2], [3], [6], [30], [31], [32], [33]. This evidence concerns the gene RB1 and breast carcinoma.